<DOC>
	<DOCNO>NCT02800954</DOCNO>
	<brief_summary>The Primary objective study compare serum level Macrophage-Colony Stimulating Factor ( M-CSF ) population patient multiple myeloma ( MM ) , population patient Monoclonal Gammopathy Undetermined Significance ( MGUS ) control population .</brief_summary>
	<brief_title>Value Macrophage-Colony Stimulating Factor New Marker Bone Lesions Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>For multiple myeloma group confirm diagnosis de novo multiple myeloma accord International Myeloma Working Group criterion bisphosphonate therapy 60 day , signature inform consent form , patient age 18 year . For monoclonal gammopathy undetermined significance ( MGUS ) group confirm diagnosis MGUS accord International Myeloma Working Group criteria signature inform consent form , patient age 18 year . For healthy control group signature inform consent form , subject age 18 year . patient thyroid parathyroid disease , osteomalacia , rheumatoid arthritis , Paget 's disease , osteoporosis , bisphosphonate therapy le 60 day , absence inform consent , patient age 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>bone lesion</keyword>
	<keyword>Macrophage-Colony Stimulating Factor</keyword>
</DOC>